Literature DB >> 6644070

Impaired H-2 expression in B16 melanoma variants.

P Nanni, M P Colombo, C De Giovanni, P L Lollini, G Nicoletti, G Parmiani, G Prodi.   

Abstract

We studied the expression of H-2b alloantigens in three different B16 melanoma lines cultures in vitro. Cell lines were B16-F1 and two cell cultures (named B16-A and B16-B) newly derived from two different in vivo sublines of B16 melanoma. The assays used were in vivo tumour growth in allogeneic (BALB/c and B10.BR) as compared to syngeneic mice, in vitro cell-mediated cytotoxicity by anti-H-2b immune lymphocytes and absorption of anti-H-2b antisera activity. The B16-F1 line was able to efficiently kill allogeneic hosts, could not be lysed by anti-H-2b cytotoxic effectors and did not express any serologically detectable amount of H-2b alloantigens. The B16-A line was H-2 positive during the early in vitro passages, then, at the 8th-10th passages, it acquired the capacity to kill allogeneic hosts, lost the sensitivity to anti-H-2b cytotoxic effectors and the H-2Kb antigens became undetectable The expression of H-2Db was reduced, although at a lower degree. Similar data were obtained with B16-B cells, which after 10 in vitro passages grew and killed allogeneic hosts, showed a decreased sensitivity to cytotoxic anti-H-2b effectors and a very low expression of the K region antigens. The results indicate that H-2 expression is altered in B16 melanoma lines and this may influence the different metastatic capacity of such cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6644070     DOI: 10.1111/j.1744-313x.1983.tb00348.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  8 in total

1.  Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma.

Authors:  P L Lollini; C De Giovanni; G Nicoletti; A Bontadini; P L Tazzari; L Landuzzi; K Scotlandi; P Nanni
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

2.  Interferon-mediated enhancement of metastasis. Are MHC antigens involved?

Authors:  P L Lollini; C De Giovanni; B Del Re; G Nicoletti; G Prodi; P Nanni
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

Review 3.  Experimental strategies for modification of histocompatibility antigens in tumor cells.

Authors:  J Vogel; K Tanaka; G S Hoekzema; G Jay
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells.

Authors:  K Tanaka; H Hayashi; C Hamada; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

5.  Allogeneic H-2 antigen expression is insufficient for tumor rejection.

Authors:  G A Cole; G A Cole; V K Clements; E P Garcia; S Ostrand-Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Effects of ozone on some biological activities of cells in vitro.

Authors:  V Cardile; X Jiang; A Russo; F Casella; M Renis; M Bindoni
Journal:  Cell Biol Toxicol       Date:  1995-02       Impact factor: 6.691

Review 7.  Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Authors:  Soledad Mac Keon; María Sol Ruiz; Silvina Gazzaniga; Rosa Wainstok
Journal:  Front Immunol       Date:  2015-05-20       Impact factor: 7.561

8.  Control of H-2 expression in transformed nonhaemopoietic cells by autocrine interferon.

Authors:  P Nanni; L Landuzzi; G Nicoletti; C De Giovanni; M Giovarelli; E Lalli; A Facchini; P L Lollini
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.